Navigation Links
Safe Options for Cardiac Lead Removal: Study Published in Heart Rhythm Journal
Date:5/12/2008

netics

Founded in 1984, Spectranetics manufactures and sells the only excimer laser approved in the United States, Europe and Japan for use in minimally invasive cardiovascular procedures. This technology treats complex cardiovascular conditions by photo-ablating multiple lesion types into tiny particles that are easily absorbed into the blood stream. The Company's disposable catheters use high-energy "cool" ultraviolet light to vaporize arterial blockages in the legs and heart, as well as scar tissue encapsulating pacing and defibrillation leads. For more information, visit http://www.spectranetics.com.

Stacey Holifield/Krystin Hayward

Schwartz Communications, Inc.,

(781) 684-0770

spectranetics@schwartz-pr.com


'/>"/>
SOURCE Spectranetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. ValueOptions(R) New Mexico Provides $10.3 Million for Community Behavioral Health Care Organizations
2. Keith Denner Extends Current Technologys Chairman and CEO Options
3. SNAPforSeniors Now Helps BenefitsCheckUp Users Locate Housing Options
4. Blue Cross Consumer-directed Health Plan - Options Blue - Members Not Sacrificing Health for the Sake of Saving Money
5. Guardian Expands Dental Benefit Options Helps Small Business Owners Lower Insurance Cost
6. NeurogesX to Present at Susquehanna Financial Groups 2nd Annual SIGnificant Options in Healthcare Conference
7. Novavax CEO to Present at Susquehannas Second SIGnificant Options in Healthcare Conference
8. Abaxis, Inc. to Present at the Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
9. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
10. Advanced Life Sciences to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference
11. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 2Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 4Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 5Patent Expiries of Blockbuster Antibiotics Will Fuel a Decline of More Than 15 Percent in the Community-Acquired Pneumonia Drug Market 2Solution to PREVENT Novel H1N1 28Swine Flu 29 From Closing Down Schools 21 55627 1Solution to PREVENT Novel H1N1 28Swine Flu 29 From Closing Down Schools 21 55627 2Congressman Schock Gets Health Care Reform Message In A Bottle From AARP 55623 1Congressman Schock Gets Health Care Reform Message In A Bottle From AARP 55623 2Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 4916 1Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 4916 2Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 4916 3Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 4916 4